Know Cancer

or
forgot password

Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia


Phase 1/Phase 2
55 Years
N/A
Not Enrolling
Both
Chronic Myeloid Leukemia

Thank you

Trial Information

Allogeneic Tumor Cell Vaccination in Patients With Chronic Myeloid Leukemia


Inclusion Criteria:



- Patients above the age of 55 consenting to participate in the study.

- Patients with documented CML with Philadelphia chromosome t (9:21)

- Patients with no HLA matched sibling.

- Patients eligible for BMT for who no matched unrelated donor can be identified after
completion of an international donor search lasting for more than six months, or
patients that have failed BMT.

- Patients with contra-indication to BMT.

- Patients refusing BMT.

- Patients who failed interferon alpha, ARAc and/or Glivec.

Exclusion Criteria:

- Patients requiring immunosuppressive therapy or corticosteroids.

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Investigate the feasibility of allogeneic tumor cell vaccine for patients with resistant CML.

Principal Investigator

Shimon Slavin, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Hadassah Medical Organization

Authority:

Israel: Israeli Health Ministry Pharmaceutical Administration

Study ID:

191199-HMO-CTIL

NCT ID:

NCT00162513

Start Date:

December 2006

Completion Date:

Related Keywords:

  • Chronic Myeloid Leukemia
  • Leukemia
  • Leukemia, Myeloid
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Name

Location